Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Eisai’s Alzheimer’s Med Leqembi Now Available in China
Eisai said on June 28 that it has launched its Alzheimer’s treatment Leqembi (lecanemab) in China, making it the third country where the drug is available, after the US and Japan. An anti-amyloid beta (Aβ) protofibril antibody, Leqembi was approved…
To read the full story
Related Article
- Eisai’s Leqembi Added to China Commercial Insurance Drug List
December 10, 2025
- China Approves Monthly IV Maintenance Dosing of Leqembi
September 30, 2025
- Leqembi Now Approved in China: Eisai/Biogen
January 10, 2024
BUSINESS
- Regenxbio Clears Path to Resubmit Hunter Syndrome Gene Therapy
June 24, 2026
- Merck Biopharma Files Lurbinectedin for SCLC in Japan
June 24, 2026
- FRONTEO Joins Dementia Prevention Cohort Study with KIBIT AI
June 24, 2026
- Alfresa Invests in Digital Health Startup eMind
June 24, 2026
- Daito Scores China Approval for Myonal Generic
June 24, 2026
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…